Cargando…
Risk of Major Cardiovascular and Cerebrovascular Events in Users of Lisdexamfetamine and Other Medications for Attention-Deficit/Hyperactivity Disorder in Denmark and Sweden: A Population-Based Cohort Study
INTRODUCTION: This study aimed to estimate risks of cardiovascular and cerebrovascular events in patients treated with lisdexamfetamine dimesylate (LDX) compared with patients previously treated with other attention-deficit/hyperactivity disorder (ADHD) medications (amphetamine, dexamphetamine, meth...
Autores principales: | Forns, Joan, Dudukina, Elena, Hägg, David, Szentkúti, Péter, Gembert, Karin, Plana, Estel, Gilsenan, Alicia, Horváth-Puhó, Erzsébet, Ehrenstein, Vera, Reutfors, Johan, Rebordosa, Cristina |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Healthcare
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9588134/ https://www.ncbi.nlm.nih.gov/pubmed/36028603 http://dx.doi.org/10.1007/s40120-022-00396-y |
Ejemplares similares
-
Lisdexamfetamine in the treatment of adolescents and children with attention-deficit/hyperactivity disorder
por: Najib, Jadwiga
Publicado: (2012) -
Review of Lisdexamfetamine Dimesylate in Adults With Attention-Deficit/Hyperactivity Disorder
por: Najib, Jadwiga, et al.
Publicado: (2017) -
Lisdexamfetamine Dimesylate for Preschool Children with Attention-Deficit/Hyperactivity Disorder
por: Childress, Ann C., et al.
Publicado: (2020) -
No Evidence of Off-label Use of Olodaterol and Indacaterol in Denmark, France, and the Netherlands: A Drug Utilization Study
por: Rebordosa, Cristina, et al.
Publicado: (2020) -
Effect of lisdexamfetamine dimesylate on sleep in adults with attention-deficit/hyperactivity disorder
por: Adler, Lenard A, et al.
Publicado: (2009)